CANCER RELEVANCE: – Colorectal (5-22%) – Papillary Thyroid (30- 80%) – Melanoma (>60%) DRUG RELEVANCE: – Anit-EGFR Therapies (cetuximab, panitumumab) – Raf and MEK small molecule inhibitors SENSITIVITY: – <1% mutant allele TURN AROUND TIME: – 4 to 6 days

Close

previous | zoom | next

BRAF mutations (V600E, V600K) are activating mutations found primarily in melanoma, thyroid, and colon tumor samples. Cancer patients harboring BRAF mutations are potential candidates of BRAF inhibitor therapies currently in various stages of clinical development. MolecularMD provides rapid, accurate, and sensitive BRAF mutation analysis on FFPE or fresh frozen tissue samples for patient selection and trial enrollment.

Our clinical assay development laboratory has validated the BRAF assay over a broad range of sample types. The allele specific, semi quantitative assay (ASQ-PCR) is rapid, sensitive, and cost-effective.

Click here to download the PDF test summary or contact MolecularMD directly for more information.